In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Assembly Biosciences (ASMB), with a price target of $30.00. The company’s shares closed last Monday at $16.62.
According to TipRanks.com, Syed is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.6% and a 43.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Assembly Biosciences with a $30.00 average price target.
See today’s analyst top recommended stocks >>
Based on Assembly Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.77 million and GAAP net loss of $27.08 million. In comparison, last year the company earned revenue of $3.74 million and had a GAAP net loss of $26.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
